Modifiedpartners_health_managementPolicy NC.CP.MP.62

Clinical Policy: Hyperhidrosis Treatments

Customize your policy alerts

Sign up for partners_health_management Policy NC.CP.MP.62 alerts

Get alerted when Policy NC.CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria and coding guidance for treatments of primary hyperhidrosis (iontophoresis, surgical excision of axillary sweat glands, endoscopic thoracic sympathectomy) for members of the Health Plan.

Policy Summary

Payerpartners_health_management

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy NC.CP.MP.62

Change TypeCriteria revisions and removal of timing requirement

Effective Date

Last ReviewJan 1, 2026

Next Review Date

Key ActionObtain prior authorization when billing referenced CPT codes and document diagnosis, prior conservative therapy, and procedure-specific counseling and contraindications.

SourceLink

POLICY UPDATE CHANGES

Updated Criteria II.B. to greater than 55 beats per minute.

Added counseling on risks of procedure as criterion III.I.

Removed six-month time frame requirement for trial of conservative management in Criteria I.D.

3treatment pathways

9iontophoresis contraindications

8CPT codes referenced

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Modifiedpartners_health_managementPolicy NC.CP.MP.62

Clinical Policy: Hyperhidrosis Treatments

Customize your policy alerts

Sign up for partners_health_management Policy NC.CP.MP.62 alerts

Get alerted when Policy NC.CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerpartners_health_management

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy NC.CP.MP.62

Change TypeCriteria revisions and removal of timing requirement

Effective Date

Last ReviewJan 1, 2026

Next Review Date

Key ActionObtain prior authorization when billing referenced CPT codes and document diagnosis, prior conservative therapy, and procedure-specific counseling and contraindications.

SourceLink

POLICY UPDATE CHANGES

Updated Criteria II.B. to greater than 55 beats per minute.

Added counseling on risks of procedure as criterion III.I.

Removed six-month time frame requirement for trial of conservative management in Criteria I.D.

3treatment pathways

9iontophoresis contraindications

8CPT codes referenced

Centenecorporate owner

Coverage Criteria for Hyperhidrosis Treatments

Iontophoresis (electrophoresis, Drionic device) — Medical necessity

Covered when ALL of the following are met

Iontophoresis criteria: A. Diagnosis of primary hyperhidrosis; B. Development of medical complications, such as skin maceration with secondary skin infections, or a significant constant disruption of professional and/or social life (e.g., recurrent changing of clothes, affecting job/social function) which has occurred because of excessive sweating; C. Failed a trial of conservative management including the adherent application of aluminum chloride hexahydrate (prescription Drysol) or topical agents have resulted in a severe rash; D. Has none of the following contraindications: (1) Cardiac pacemaker; (2) Cardiac arrhythmias; (3) Pregnancy; (4) Metal implants, depending on size and position (may divert the electric current); (5) Epilepsy

All elements required

Surgical excision of axillary sweat glands — Medical necessity

Covered when ALL of the following are met

Axillary excision criteria: A. Meets all of the iontophoresis criteria in I.A. through I.D.; B. Persistent and severe primary hyperhidrosis; C. Has failed one of the following: (1) Iontophoresis; (2) Trial of botulinum toxin.

All elements required

Endoscopic thoracic sympathectomy (ETS) — Medical necessity

Covered when ALL of the following are met

ETS criteria: A. Meets all of the iontophoresis criteria in I.A. through I.D.; B. Member/enrollee has a resting heart rate > 55 beats per minute; C. Hyperhidrosis symptoms started at an early age (usually < 16 years), and surgery is requested for a young member/enrollee (usually < 25 years of age); D. Body mass index < 28; E. Reports no sweating during sleep; F. Member/enrollee has no significant comorbidities; G. Member/enrollee has persistent and severe primary hyperhidrosis; H. Member/enrollee has failed one of the following: (1) Iontophoresis; (2) Trial of botulinum toxin for predominantly axillary hyperhidrosis; I. Member/enrollee has been counseled on risks of procedure.

All elements required

This policy notes that, beyond the specific treatments with defined medical necessity criteria (iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy), there are other treatments that have been evaluated in the literature. The document states that there is insufficient evidence in published peer‑reviewed literature to support all other treatments for hyperhidrosis, and highlights that this includes, but is not limited to, microwave therapy and liposuction used as the sole method for axillary sweat gland removal. This limitation means such approaches are not supported by this policy and should not be considered medically necessary under the policy's coverage criteria.

Coverage determinations under this clinical policy are made in the context of the member's specific benefit plan. All coverage is subject to the terms, conditions, exclusions and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract of insurance), as well as applicable state and federal requirements and Health Plan administrative policies. The policy is a guide to medical necessity and does not guarantee payment; discrepancies are governed by law and plan documents.

The policy addresses technologies proposed for axillary hyperhidrosis and specifically notes limitations of the evidence. Although microwave energy devices (for example, the miraDry System) have received FDA clearance for treatment of primary axillary hyperhidrosis, the clinical policy explicitly states there is insufficient peer‑reviewed evidence to support microwave therapy or liposuction when used as the sole method of removing axillary sweat glands. As a result, these approaches are not supported by this policy and are treated as unsupported/insufficient‑evidence options.

Coding and Clinical Thresholds

Referenced CPT CodesCPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877	Suction assisted lipectomy; trunk.
15878	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes.

inv-09: Resting heart rate for ETS consideration — key clinical threshold (> 55 beats per minute)

Resting heart rate thresholdMember/enrollee has a resting heart rate > 55 beats per minute

ContextRequired specifically as Criterion III.B. for endoscopic thoracic sympathectomy (ETS)

Relation to other criteriaMust be present in addition to meeting iontophoresis criteria I.A.–I.D. and other ETS criteria (e.g., BMI, age of onset)

inv-10: Body mass index threshold for ETS consideration — key clinical threshold (< 28)

Body mass index thresholdBody mass index < 28

ContextSpecified as Criterion III.D. for endoscopic thoracic sympathectomy (ETS)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required for referenced CPT codes

Prior authorization is required when billing the CPT codes referenced in this policy; coverage is contingent on meeting the policy's medical necessity criteria.

Referenced CPT codes include: 11450, 11451, 15877, 15878, 32664, 97024, 97033.
Claims submitted using these CPT codes should have prior authorization per the Health Plan's processes and must meet the applicable coverage criteria in this policy.

Note

Policy used in coverage decisioning and benefit administration

This clinical policy is a guide used to assist in making coverage decisions and administering benefits; prior authorization requirements should follow the Health Plan's administrative policies and the member's coverage documents.

The policy provides medical necessity guidance but does not guarantee payment.
Prior authorization processes must align with applicable Health Plan-level administrative policies and procedures.

Definitions

inv-20: Primary hyperhidrosis — definition and characteristic features (duration, common locations)

DefinitionPrimary hyperhidrosis: idiopathic focal excessive sweating induced by sympathetic hyperactivity not associated with an underlying disease process

Duration criterionCharacterized by visible, excessive sweating of at least six months' duration

Common locationsMost common locations are underarms (axillary), hands (palmar), and feet (plantar)

ImpactCan cause ruined clothing, emotional distress, and occupational disability due to functional and social impairment

inv-21: Secondary hyperhidrosis — definition and typical causes (drugs, underlying conditions)

DefinitionSecondary hyperhidrosis: excessive sweating resulting from medications or underlying conditions rather than idiopathic sympathetic overactivity

Background

Primary focal hyperhidrosis is an idiopathic condition characterized by localized excessive sweating most commonly affecting the axillae, palms, and soles. It is typically chronic and can cause marked functional impairment or social and occupational disruption. A variety of therapies have been studied — topical aluminum chloride preparations, iontophoresis, intradermal botulinum toxin, endoscopic thoracic sympathectomy (ETS), and surgical excision of axillary sweat glands — with ETS considered a last‑resort option because of the potential for serious, irreversible compensatory sweating and other adverse effects.

Revision History

2025-02criteria_update

Updated multiple criteria: removed phrase 'in response to heat exposure or exercise', updated criteria I.E.3 and I.E.5 (added epilepsy), and revised cross-references in Criteria II.A and III.A; added diathermy to coding notation for insufficient evidence.

2024-03criteria_addition

Added criterion III.I requiring member/enrollee counseling on risks of endoscopic thoracic sympathectomy (ETS) and reordered criteria; removed CPT codes 64802–64823.

2023-01threshold_change

Policy Summary

Payerpartners_health_management

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy NC.CP.MP.62

Change TypeCriteria revisions and removal of timing requirement

Effective Date

Last ReviewJan 1, 2026

Next Review Date

Key ActionObtain prior authorization when billing referenced CPT codes and document diagnosis, prior conservative therapy, and procedure-specific counseling and contraindications.

SourceLink

On This Page

Relation to other criteriaRequired alongside resting heart rate >55 bpm, early symptom onset, no sweating during sleep, and other ETS elements

Step Therapy

Step therapy / prior trial requirements for surgical procedures

Surgical excision of axillary sweat glands and ETS require prior trials as specified in the medical necessity criteria: axillary excision requires failure of iontophoresis or a trial of botulinum toxin; ETS requires failure of iontophoresis or trial of botulinum toxin for predominantly axillary cases.

Axillary excision criterion III.C: failed one of the following — (1) Iontophoresis; (2) Trial of botulinum toxin.
ETS criterion III.H: failed one of the following — (1) Iontophoresis; (2) Trial of botulinum toxin for predominantly axillary hyperhidrosis.

Step Therapy

No other specific step therapy requirements specified

The policy text also notes that no additional specific step therapy requirements beyond the listed failed trials are specified in the referenced administrative chunks.

Where no specific step therapy requirements are provided, follow the explicit trial/failure elements listed in the medical necessity criteria.
Administrative or plan-level step therapy programs (if any) should be applied according to Health Plan procedures.

Documentation Required

Required documentation to support medical necessity

Documentation submitted for authorization must demonstrate a diagnosis of primary hyperhidrosis and describe medical complications or substantial professional/social disruption attributable to excessive sweating.

Include evidence of failed conservative management (e.g., adherent use of aluminum chloride hexahydrate or intolerable severe rash from topical agents) and any prior trials of iontophoresis or botulinum toxin as applicable.
For ETS requests, include documentation of counseling on risks of the procedure where required by the criteria.

Documentation Required

Providers must exercise professional medical judgment

Providers are expected to exercise professional medical judgment; this clinical policy is a guide to medical necessity and is not intended to dictate clinical care or substitute for provider decision-making.

Providers remain solely responsible for medical advice and treatment of members/enrollees.
The policy does not constitute medical advice, a contract, or a guarantee of payment.

Denial Risk

Denial risk if medical necessity criteria are not met

Requests that do not meet the listed medical necessity criteria (e.g., diagnosis of primary hyperhidrosis; required complications or life disruption; failed conservative management; absence of contraindications; and procedure‑specific elements) risk denial.

Denials can occur when required trials (iontophoresis, botulinum toxin) or documented complications/social/professional impact are not provided.
Ensure all elements of the applicable criteria set are clearly documented to reduce denial risk.

Note

Coverage subject to plan terms, exclusions, limitations

Coverage decisions and administration of benefits are subject to all terms, conditions, exclusions and limitations of the member's coverage documents and applicable law and plan administrative policies.

If there is a discrepancy between this clinical policy and legal/regulatory requirements, law and regulation govern.
The Health Plan may change, amend, or withdraw this policy at any time; the policy does not guarantee coverage.

Typical drug causesMay result from drugs such as tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs)

Typical underlying conditionsCan be due to febrile illnesses, diabetes mellitus, or menopause; often presents as generalized or craniofacial sweating

Distinct patternsSecondary gustatory hyperhidrosis typically occurs symmetrically on scalp or face after spicy foods; facial gustatory sweating is often asymmetrical and may follow parotid-region injury/surgery

inv-22: Health Plan — definition of the health plan adopting this policy and Centene ownership/administration context

Definition of Health PlanA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or an affiliate

Purpose of policyThis clinical policy is a guide to medical necessity used to assist in making coverage decisions and administering benefits; it is not a contract or guarantee of payment

Applicability and governanceCoverage decisions are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and to state and federal requirements

Updated Criteria II.B to specify resting heart rate greater than 55 beats per minute and removed phrase 'is relatively healthy' from Criteria II.F; background updated with no impact to criteria.

2023-04administrative_adaptation

Policy adapted for use by North Carolina Health Plan with removal of references to selected pharmacy policies and other administrative edits.

2022-01format_and_terminology_changes

Annual review with revisions to header date labels and replacement of 'experimental/investigational' language with descriptive wording; references reviewed and updated.